Trial Profile

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rosuvastatin (Primary)
Indications Hyperlipidaemia; Lipid metabolism disorders
Focus Therapeutic Use
Acronyms EMERALD

Most Recent Events

23 May 2024 According to EISAI media release, announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology Annual Meeting which is taking place virtually and inperson in Chicago, Illinois from May 31 to June 4.
02 Aug 2023 Status changed from active, no longer recruiting to completed.
30 Jun 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com